WGND Co-chair, Barbara Laughon, and Sequella Inc. CEO, Carol Nacy, co-authored a correspondence to Nature Reviews regarding the October 2016 Article, “Tuberculosis”.
“In their recent Primer article (Tuberculosis. Nat. Rev. Dis. Primers 2, 16076 (2016))1, Madhukar Pai and colleagues give an important and comprehensive update on the advances made in epidemiology, diagnosis, prevention and treatment for combatting the global tuberculosis (TB) epidemic. The Primer included the global TB drug pipeline (Figure 5) that represented the status of the field as of April 2016. However, several important new developments were reported at two major scientific conferences later in 2016: the EMBO Conference Tuberculosis 2016 in Paris, France, 19–23 September 2016 (http://www.tuberculosis2016.org), and the 47th Union World Congress on Lung Health and associated meetings in Liverpool, UK, 26–29 October 2016 (http://liverpool.worldlunghealth.org/). We believe that updates to the 2016 status of the TB drug pipeline would be of interest to readers of the journal…”
Continue reading here: http://www.nature.com/articles/nrdp201715